{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-009952","form_type":"8-K","ticker":"ANEB","cik":"0001815974","company_name":"Anebulo Pharmaceuticals, Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.843859+00:00","generated_at":"2026-05-21T17:25:53.522109+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Anebulo reports Q3 net loss $1.7M; advancing IV selonabant for pediatric cannabis toxicity","bullets":["Operating expenses $1.9M in Q3 fiscal 2025 vs $1.7M year ago.","Net loss $1.7M ($0.04/share) vs $1.7M ($0.06/share) in prior year.","Cash $13.3M plus $3M loan facility; sufficient for planned operations.","Prioritizing IV selonabant for pediatric CNS depression; Phase 1 SAD study to start Q3 2025.","FDA confirmed unmet need for pediatric cannabis toxicity treatment; collaboration suggested."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-009952","json":"https://secwatch.observer/filing/0001641172-25-009952.json","markdown":"https://secwatch.observer/filing/0001641172-25-009952.md","text":"https://secwatch.observer/filing/0001641172-25-009952.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815974/000164117225009952/0001641172-25-009952-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815974/000164117225009952/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T17:25:53.522109+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}